BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Chang-Jiang Lei, Jia-Ni Liu, Rong Wu, Zhi-Xiong Long, Jiang-Zhou Zhang, Dan Tao, Yan-Ping Liu. Change of the peripheral blood immune pattern and its correlation with prognosis in patients with liver cancer treated by sorafenibAsian Pacific Journal of Tropical Medicine 2016; 9(6): 592 doi: 10.1016/j.apjtm.2016.04.019
2
Beste Yurdacan, Unal Egeli, Gamze Guney Eskiler, Isil Ezgi Eryilmaz, Gulsah Cecener, Berrin Tunca. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acidJournal of Pharmacy and Pharmacology 2019; 71(7): 1119 doi: 10.1111/jphp.13097
3
Sara Jaramillo, Francisco J.G. Muriana, Rafael Guillen, Ana Jimenez-Araujo, Rocio Rodriguez-Arcos, Sergio Lopez. Saponins from edible spears of wild asparagus inhibit AKT, p70S6K, and ERK signalling, and induce apoptosis through G0/G1 cell cycle arrest in human colon cancer HCT-116 cellsJournal of Functional Foods 2016; 26: 1 doi: 10.1016/j.jff.2016.07.007
4
Shanshan Jiang, Qian Wang, Meiqing Feng, Jiyang Li, Zhongbin Guan, Duopeng An, Mengxue Dong, Yuzhe Peng, Kudelaidi Kuerban, Li Ye. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cellsApplied Microbiology and Biotechnology 2017; 101(4): 1535 doi: 10.1007/s00253-016-7930-9
5
Rui Zhang, Min Ma, Gang Dong, Rong-Rong Yao, Jing-Huan Li, Qiong-Dan Zheng, Yin-Ying Dong, Hui Ma, Dong-Mei Gao, Jie-Feng Cui, Zheng-Gang Ren, Rong-Xin Chen. Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatmentCancer Science 2017; 108(9): 1778 doi: 10.1111/cas.13322
6
Diego Almanza, Mehrnaz Gharaee-Kermani, Alisa Zhilin-Roth, Jose A. Rodriguez-Nieves, Cory Colaneri, Todd Riley, Jill A. Macoska. Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular SignatureDigestive Diseases and Sciences 2019; 64(5): 1257 doi: 10.1007/s10620-018-5398-4
7
Bijay Dhungel, Charmaine A. Ramlogan-Steel, Christopher J. Layton, Jason C. Steel. MicroRNA199a-Based Post-transcriptional Detargeting of Gene Vectors for Hepatocellular CarcinomaMolecular Therapy - Nucleic Acids 2018; 13: 78 doi: 10.1016/j.omtn.2018.08.016
8
Mohammed K. AbdElhameid, Madlen B. Labib, Ahmed T. Negmeldin, Muhammad Al-Shorbagy, Manal R. Mohammed. Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2InhibitorsJournal of Enzyme Inhibition and Medicinal Chemistry 2018; 33(1): 1472 doi: 10.1080/14756366.2018.1503654
9
Francesca Mastropasqua, Flaviana Marzano, Alessio Valletti, Italia Aiello, Giuseppe Di Tullio, Annalisa Morgano, Sabino Liuni, Elena Ranieri, Luisa Guerrini, Giuseppe Gasparre, Elisabetta Sbisà, Graziano Pesole, Antonio Moschetta, Mariano Francesco Caratozzolo, Apollonia Tullo. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumoursMolecular Cancer 2017; 16(1) doi: 10.1186/s12943-017-0634-7
10
Fang Wang, Thomas Bank, Gregory Malnassy, Maribel Arteaga, Na Shang, Annika Dalheim, Xianzhong Ding, Scott J. Cotler, Mitchell F. Denning, Michael I. Nishimura, Peter Breslin, Wei Qiu. Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survivalHepatology Communications 2018; 2(6): 732 doi: 10.1002/hep4.1181
11
Ming-Hua Hsu, Shih-Ming Hsu, Yu-Cheng Kuo, Chih-Yu Liu, Cheng-Ying Hsieh, Yuh-Ching Twu, Chung-Kwe Wang, Yuan-Hsi Wang, Yi-Jen Liao. Treatment with low-dose sorafenib in combination with a novel benzimidazole derivative bearing a pyrolidine side chain provides synergistic anti-proliferative effects against human liver cancerRSC Advances 2017; 7(26): 16253 doi: 10.1039/C6RA28281D
12
Zhuona Rong, Tingting Fan, Huiling Li, Juan Li, Kangwei Wang, Xinxin Wang, Jianyi Dong, Jun Chen, Fujin Wang, Jingyu Wang, Aiguo Wang. Differential Proteomic Analysis of Gender-dependent Hepatic Tumorigenesis in Hras12V Transgenic MiceMolecular & Cellular Proteomics 2017; 16(8): 1475 doi: 10.1074/mcp.M116.065474
13
Liyu Shi, Xiaoqiu Zheng, Yuzhuo Fan, Xiaolan Yang, Aimei Li, Jun Qian. The contribution of miR-122 to the innate immunity by regulating toll-like receptor 4 in hepatoma cellsBMC Gastroenterology 2019; 19(1) doi: 10.1186/s12876-019-1048-3
14
Tian-yi Zhou, Lin-han Zhuang, Yan Hu, Yu-lu Zhou, Wen-kai Lin, Dan-dan Wang, Zi-qian Wan, Lin-lin Chang, Ying Chen, Mei-dan Ying, Zi-bo Chen, Song Ye, Jian-shu Lou, Qiao-jun He, Hong Zhu, Bo Yang. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cellsScientific Reports 2016; 6(1) doi: 10.1038/srep30483
15
Menelaos Zafrakas, Panayiota Papasozomenou, Christos Emmanouilides. Sorafenib in breast cancer treatment: A systematic review and overview of clinical trialsWorld Journal of Clinical Oncology 2016; 7(4): 331-336 doi: 10.5306/wjco.v7.i4.331
16
Zhao-Shan Niu, Xiao-Jun Niu, Wen-Hong Wang. Genetic alterations in hepatocellular carcinoma: An updateWorld Journal of Gastroenterology 2016; 22(41): 9069-9095 doi: 10.3748/wjg.v22.i41.9069
17
Peter Dietrich, Andreas Koch, Valerie Fritz, Arndt Hartmann, Anja Katrin Bosserhoff, Claus Hellerbrand. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistanceGut 2018; 67(7): 1328 doi: 10.1136/gutjnl-2017-315402
18
MK Morris, DC Clarke, LC Osimiri, DA Lauffenburger. Systematic Analysis of Quantitative Logic Model Ensembles Predicts Drug Combination Effects on Cell Signaling NetworksCPT: Pharmacometrics & Systems Pharmacology 2016; 5(10): 544 doi: 10.1002/psp4.12104
19
Jing Li, Jinfeng Wang, Wei Zhou, Shuqin Zhang, Yuan Le, Rong He. Downregulation of BRAF-activated non-coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cellsOncology Letters 2017; 14(4): 4751 doi: 10.3892/ol.2017.6770
20
Maximilian A. Ardelt, Thomas Fröhlich, Emanuele Martini, Martin Müller, Veronika Kanitz, Carina Atzberger, Petra Cantonati, Martina Meßner, Laura Posselt, Thorsten Lehr, Jan-Georg Wojtyniak, Melanie Ulrich, Georg J. Arnold, Lars König, Dario Parazzoli, Stefan Zahler, Simon Rothenfußer, Doris Mayr, Alexander Gerbes, Giorgio Scita, Angelika M. Vollmar, Johanna Pachmayr. Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma TherapyHepatology 2019; 69(1): 376 doi: 10.1002/hep.30190
21
Shuzhen Chen, Qiqi Cao, Wen Wen, Hongyang Wang. Targeted therapy for hepatocellular carcinoma: Challenges and opportunitiesCancer Letters 2019; 460: 1 doi: 10.1016/j.canlet.2019.114428
22
Guirong Zheng, Ruirui Zhao, Aixiao Xu, Zhichun Shen, Xian Chen, Jingwei Shao. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapyEuropean Journal of Pharmaceutical Sciences 2018; 111: 492 doi: 10.1016/j.ejps.2017.10.036